This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
The first description of primary sclerosing cholangitis (PSC) dates from a case report by Delbet in 1867 on sclerotic changes of the bile ducts. Subsequently, in the early 20th century, several surgeons reported cases of obstructive jaundice with fibrous strictures of the bile ducts, but no clear distinction was made from secondary (postoperative, postinfectious) bile duct strictures. The name 'PSC' was first used in 1958 by Warren, Athanassiades, and Monge in describing a group of patients presenting with benign non-calculous bile duct strictures, and they proposed that it was an idiopathic sclerosing bile duct disease of unknown cause.
With the introduction of endoscopic retrograde cholangiopancreatography (ERCP) into clinical practice in the 1970s, a breakthrough was achieved in the diagnosis of PSC. ERCP identified the characteristic cholangiographic finding of a 'beads on a string' appearance with alternating multifocal strictures and dilations of the bile ducts, and diagnosis of PSC and epidemiological research developed rapidly. In the 1980s, the strong association between PSC and inflammatory bowel disease (especially ulcerative colitis) was systematically demonstrated, and through this an autoimmune or gut-liver axis-mediated pathogenesis of PSC began to attract attention.
In terms of treatment, ursodeoxycholic acid (UDCA) was studied in the 1990s as a possible treatment for PSC, but a large randomized controlled trial published in 2008 (Lindor, NEJM 2009) confirmed that high-dose UDCA (28–30 mg/kg/day) failed to reduce the composite clinical events of liver transplantation, liver cancer, cholangiocarcinoma, and death and could instead increase the risk of complications; thereafter, general use of UDCA in PSC was no longer recommended. Since the 1990s, liver transplantation has become established as the only proven treatment for advanced PSC, and long-term outcomes after transplantation have also improved greatly.
Since the 2000s, MRCP (magnetic resonance cholangiopancreatography) has replaced ERCP as the primary diagnostic imaging technique, enabling noninvasive diagnosis. In the 2010s, genome-wide association studies (GWAS) identified multiple PSC susceptibility loci beyond HLA, such as CARD9, FUT2, and SH2B3. In the 2020s, clinical trials of numerous new drugs, including FXR agonists (obeticholic acid), PPAR agonists, and antifibrotic agents, are under way, and research on pathogenesis using bile duct organoid-based models is also actively being conducted.
The exact etiology of PSC has not yet been fully elucidated; it is understood that immune abnormalities, changes in the gut microbiota, and abnormal bile acid metabolism act in combination in genetically susceptible individuals.
Immune mechanisms: PSC is sometimes not classified as an autoimmune disease, but it shares many autoimmune features. Autoantibodies such as perinuclear ANCA (pANCA), ANA, and ASMA are detected in patient serum, and CD4+ T cells, CD8+ T cells, and natural killer (NK) T cells infiltrate abundantly around the bile ducts and in the portal tracts. Biliary epithelial cells (cholangiocytes) aberrantly express HLA class II molecules, which may promote injury by autoreactive T cells. However, PSC differs from typical autoimmune diseases in that it does not respond to immunosuppressive treatment (steroids, AZA, cyclosporine, etc.).
Association with inflammatory bowel disease (IBD): IBD (mainly ulcerative colitis, some Crohn disease) coexists in about 60–80% of PSC patients, and conversely PSC develops in about 2–5% of patients with ulcerative colitis. The strong association between IBD and PSC suggests a role for the gut-liver axis. Through increased intestinal mucosal permeability, bacterial products (LPS, bacterial DNA) may enter the portal circulation and activate innate and adaptive immunity in the liver. It has also been suggested that dysbiosis of the gut flora in IBD increases the risk of PSC.
Bile acid toxicity: In PSC, hydrophobic bile acids accumulate in the liver·bile ducts owing to cholestasis and exert cytotoxicity, forming a vicious cycle that promotes fibrosis. Abnormal metabolism of normal hydrophilic bile acids (UDCA) may also contribute to the development of PSC.
Microbiota and the bilome: Recent studies suggest that the microbial composition of bile (bilome) in PSC patients differs from that of healthy people, and that specific bacterial species (Fusobacterium, Prevotella, etc.) may cause or promote bile duct inflammation. The possibility of treating PSC through microbiota modulation, such as fecal microbiota transplantation (FMT), is being explored.
PSC is a complex multifactorial disease with a strong genetic component, with the HLA region and multiple non-HLA loci involved in susceptibility. HLA-B8, HLA-DR3 (DRB1*03:01), and HLA-DR2 (DRB1*15:01) are known PSC susceptibility alleles; these are HLA haplotypes shared with AIH and other autoimmune diseases. In contrast, HLA-DRB1*04 shows a protective effect against PSC.
GWAS studies have identified many non-HLA loci associated with PSC. CARD9 (caspase recruitment domain family member 9), a gene involved in innate immune signaling and recognition of gut microbes, has been identified as a susceptibility locus in both PSC and IBD. FUT2 (fucosyltransferase 2) affects blood group and expression of intestinal mucosal glycoproteins and may modulate PSC risk by changing the composition of the gut microbiota. GPR35 (G protein-coupled receptor 35) encodes a receptor related to bile acids and immune responses.
SH2B3 (regulation of lymphocyte signaling, JAK-STAT pathway), MMEL1-TNFRSF14 (upstream of TNF receptor), and TCF4 (transcription factor) have also been identified as PSC susceptibility loci. Interestingly, many PSC loci are shared with ulcerative colitis and Crohn disease, reflecting a common genetic background of PSC and IBD. On the other hand, there are also some loci that differ between PSC and IBD, suggesting that PSC is not simply a hepatic complication of IBD but a disease with independent genetic components.
In monozygotic twin studies, the concordance rate for PSC is relatively low at less than about 10%, suggesting that interaction with environmental factors is important. The risk of PSC within families is reported to be about 10–39 times that of the general population.
PSC is the most studied rare hepatobiliary disease in Northern Europe and North America, with an annual incidence reported at 0.5–1.3 per 100,000 population and a prevalence of 3.9–16.2 per 100,000 population. In Europe, incidence is relatively high in Northern Europe, such as Norway and Sweden.
The sex distribution is markedly higher in men, with a male:female ratio of about 2:1. This is a feature contrasting with PBC (female predominance). The median age of onset is in the 30s–40s, and it can also occur in children. Compared with adults, pediatric PSC tends to have a higher proportion of AIH-PSC overlap syndrome and also a higher proportion of small bile duct involvement (small-duct PSC).
Regarding the rate of coexisting IBD, IBD is present in about 60–80% of PSC patients, of which about 80% is ulcerative colitis and about 10–15% Crohn disease. Ulcerative colitis with PSC has a 4–5 times higher risk of colorectal cancer than ulcerative colitis without PSC, so more intensive colonoscopic surveillance is needed.
Epidemiological data on PSC in East Asia, including Korea, are limited compared with the West. The prevalence of IBD has recently been increasing rapidly in East Asia, and a corresponding increase in PSC incidence is also being reported. In Japan, PSC prevalence is reported at about 2–4 per 100,000 population.
Small-duct PSC accounts for about 5–15% of all PSC and is a form in which there are no bile duct abnormalities on MRCP/ERCP and characteristic PSC findings appear only on liver biopsy. Compared with large-duct PSC, the risk of cholangiocarcinoma is lower and the prognosis is better, but about 20–25% progress to large-duct PSC.
The pathogenesis of PSC centers on a vicious cycle that begins with immune-mediated injury of biliary epithelial cells (cholangiocytes) and leads to periductal fibrosis, cholestasis, and consequent secondary bile duct injury.
Immune targeting of biliary epithelial cells: PSC biliary epithelial cells aberrantly express HLA class I and II and overexpress adhesion molecules (ICAM-1, VCAM-1) and chemokines (CCL2, CXCL10), inducing periductal infiltration of T cells, natural killer cells, and neutrophils. The infiltrating immune cells secrete IFN-γ, TNF-α, IL-17, etc., causing injury and death of biliary epithelial cells.
Gut-liver axis and abnormal homing: In PSC, a mechanism by which gut-derived lymphocytes abnormally home to the liver is attracting attention. Normal gut lymphocytes home to the gut via vascular endothelial cells expressing MAdCAM-1 (mucosal addressin cell adhesion molecule). However, in the PSC liver, MAdCAM-1 is aberrantly expressed on portal tract endothelial cells within the liver, so gut-homing lymphocytes may mistakenly enter the liver. This 'aberrant homing' mechanism is supported by the observation that vedolizumab (anti-α4β7 integrin antibody) suppressed liver inflammation in animal models of PSC. However, the therapeutic effect of vedolizumab on PSC in clinical trials is still unclear.
Periductal fibrosis ('onion skin' pattern): Chronic bile duct inflammation leads to concentric fibrosis around the bile ducts (periductal concentric fibrosis, 'onion skin' appearance). Excessive collagen production occurs in activated hepatic stellate cells and portal fibroblasts through TGF-β1 and PDGF signaling. The repeated process of bile duct inflammation-fibrosis-stricture worsens cholestasis, leading to secondary bile duct injury and cirrhosis.
Bile acid-mediated toxicity: Intrahepatic accumulation of hydrophobic bile acids (e.g., lithocholic acid, deoxycholic acid) due to cholestasis exerts direct cytotoxicity on biliary epithelial cells and hepatocytes. This worsens liver injury through mitochondrial damage, oxidative stress, and apoptosis. Regulation of bile acid signaling through activation of FXR (farnesoid X receptor) and TGR5 is being studied as a treatment target for PSC.
The clinical symptoms of PSC range from asymptomatic to end-stage liver disease, and the symptom profile differs according to how the diagnosis is made. As the number of patients discovered incidentally during IBD follow-up increases, the proportion diagnosed in the asymptomatic phase has risen. However, many patients are still diagnosed a considerable time after symptom onset.
Cholestasis-related symptoms: Pruritus is one of the most common and distressing symptoms, characteristically generalized pruritus that worsens especially at night. Jaundice (scleral icterus, skin jaundice) appears with considerably advanced bile duct strictures or a dominant stricture. A dominant stricture means a significant stricture of the common bile duct or common hepatic duct and can cause abrupt worsening of jaundice and cholangitis. Xanthomas and xanthelasma may appear owing to long-standing hypercholesterolemia.
Bacterial cholangitis: Bacterial cholangitis may recur owing to cholestasis caused by bile duct strictures. It presents with Charcot's triad of fever and chills, right upper quadrant pain, and jaundice, and carries a risk of progressing to sepsis. The risk of cholangitis increases after intrabiliary procedures (stent placement, etc.).
Systemic symptoms: Fatigue, malaise, anorexia, and weight loss are common and are related to the severity of active hepatobiliary disease. Abdominal discomfort and dull right upper quadrant pain are also reported. Night blindness, osteoporosis, and bleeding tendency due to malabsorption of fat-soluble vitamins (A, D, E, K) may also appear.
End-stage complications: With progression to cirrhosis, complications of portal hypertension such as ascites, lower-extremity edema, esophageal·gastric fundal variceal bleeding, and hepatic encephalopathy develop. Cholangiocarcinoma (CCA) is the most serious complication of PSC, occurring in about 7–15% of PSC patients over their lifetime. CCA is asymptomatic or nonspecific until it is advanced, making early detection difficult.
In early PSC, physical examination findings may be normal or nonspecific. As the disease progresses, various signs due to cholestasis and cirrhosis appear.
Jaundice (scleral icterus) is observed when bile duct strictures become marked or with a dominant stricture, bacterial cholangitis, or end-stage liver failure. Jaundice in PSC tends to fluctuate intermittently, so changes in jaundice over time help in diagnosis and assessment of the course. Hepatomegaly is palpable as soft hepatomegaly during active cholestasis and may show nodular firmness at the cirrhosis stage. Splenomegaly: when portal hypertension has developed, the spleen enlarges to become palpable.
Skin excoriations (scratch marks) due to pruritus are characteristically observed. Cutaneous xanthomas and xanthelasma may develop owing to long-standing hypercholesterolemia. As signs of end-stage liver disease, spider angiomas, palmar erythema, ascites (abdominal distension, fluid wave), and esophageal varices (endoscopic finding) appear. Bleeding findings such as bruising, gum bleeding, and epistaxis due to malabsorption of fat-soluble vitamin K may also be seen.
In PSC patients with IBD, intestinal findings according to IBD activity (abdominal pain, bloody mucoid stool, diarrhea) may be present at the same time. Notably, in IBD with PSC, IBD activity does not necessarily parallel liver disease activity, so the two diseases must be managed independently.
Population-based general screening for PSC is not recommended. However, PSC should be actively considered when abnormal liver function is found in IBD patients (especially ulcerative colitis).
Serum biochemical tests: The most characteristic biochemical abnormality in PSC is elevation of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). ALP elevation reflects cholestasis, and elevations of 3–5 times normal or more are common. Aminotransferases (AST, ALT) may be moderately elevated or normal. Bilirubin may be normal early but rises markedly with a dominant stricture.
Autoantibodies and immunoglobulins: Serum perinuclear ANCA (pANCA) is positive in about 50–80% of PSC patients, but its specificity is low, so its diagnostic value alone is limited. ANA and ASMA are also positive in some. IgG4 measurement is essential for differentiation from IgG4-related sclerosing cholangitis (IgG4-SC); IgG4 >2 times the upper limit of normal strongly suggests IgG4-SC. Total IgG may be mildly elevated in PSC but not as markedly as in AIH.
Imaging tests: Abdominal ultrasound is the first-line imaging test for assessing cirrhosis, bile duct dilation, gallbladder abnormalities, intrahepatic masses, etc. MRCP is the primary noninvasive imaging technique for diagnosing PSC and shows multifocal strictures and dilations of the intrahepatic·extrahepatic bile ducts with high sensitivity·specificity.
PSC is diagnosed by combining characteristic cholangiographic findings (alternating multifocal strictures and dilations) with cholestatic liver function abnormalities. Secondary sclerosing cholangitis (ISC; due to gallstones, surgery, ischemia, IgG4-SC, etc.) must be excluded.
MRCP (magnetic resonance cholangiopancreatography): The standard primary imaging technique for diagnosing PSC. A 'beads on a string' or 'pruned tree' appearance, with alternating multifocal strictures and dilations of the intrahepatic·extrahepatic bile ducts, is characteristic. MRCP is noninvasive and involves no radiation exposure, so it can also be used for follow-up. The sensitivity·specificity of MRCP for diagnosing PSC is about 80–86%/92–99%.
ERCP (endoscopic retrograde cholangiopancreatography): Performed when MRCP is inconclusive, or when a dominant stricture is suspected and brush cytology·biopsy (to exclude cholangiocarcinoma), endoscopic biliary dilation (balloon dilation), or stent placement is needed. ERCP for diagnostic purposes alone has decreased markedly since being replaced by MRCP.
Liver biopsy: In large-duct PSC, the diagnosis can be made from cholangiographic findings, so liver biopsy is not essential. However, liver biopsy is useful in small-duct PSC, when AIH-PSC overlap syndrome is suspected, or when cholangiographic findings are atypical. Histological findings appear in stages: early periductal edema, 'onion skin' concentric fibrosis, bile duct loss, and late biliary cirrhosis (Ludwig four-stage classification).
Differentiation from IgG4-related sclerosing cholangitis (IgG4-SC): IgG4-SC may have imaging findings similar to PSC, but is characterized by elevated serum IgG4 (>2 times the upper limit of normal), a dramatic response to steroid treatment, and involvement of organs other than the bile ducts (pancreas, etc.). Because IgG4-SC can be relieved by steroid treatment, differentiating it from PSC is clinically very important.
There is currently no established drug therapy for PSC, and liver transplantation is the only established treatment for advanced PSC. Treatment strategy focuses on management of complications, improvement of quality of life, and early detection of cholangiocarcinoma.
UDCA (ursodeoxycholic acid): Low to moderate doses (13–15 mg/kg/day) improve liver function values such as ALP and GGT, but there is no evidence that they improve clinical events such as development of cholangiocarcinoma, liver transplantation, or death. High doses (28–30 mg/kg/day) may instead increase clinical events and are not recommended. Current European guidelines do not routinely recommend UDCA in PSC, but in some clinical settings low doses are used to relieve symptoms such as pruritus.
Endoscopic treatment of dominant strictures: When a dominant stricture (about 45–58% of all PSC) causes jaundice or cholangitis, endoscopic balloon dilation via ERCP is the first-line treatment. Short-term plastic stent placement is used to prevent restenosis after dilation, but long-term metal stents are generally avoided. Prophylactic antibiotics (e.g., ciprofloxacin) are commonly used after endoscopic treatment to prevent bacterial cholangitis.
Treatment of pruritus: Cholestyramine (a bile acid sequestrant) is the first-line agent but may be poorly tolerated. Rifampin 150–300 mg/day is used as second-line treatment, with relief of pruritus through activation of PXR (pregnane X receptor) as the mechanism. Opioid antagonists (naltrexone, nalmefene) are also options. For severe refractory pruritus, plasma exchange and biliary diversion are attempted.
Liver transplantation: Indications for liver transplantation in PSC are end-stage liver disease (recurrent bacterial cholangitis, hepatic encephalopathy, ascites, variceal bleeding, impaired hepatocellular function), MELD score ≥15, or uncontrollable deterioration in quality of life. The 5-year survival after transplantation for PSC is about 85–90%, and PSC recurs after transplantation in about 20–25%. Caution is needed because coexisting IBD may worsen after transplantation.
Treatments under investigation: Numerous drugs, including FXR agonists (obeticholic acid, cilofexor), PPAR-α/δ agonists (bezafibrate, elafibranor), NOX1/4 inhibitors (setanaxib), antifibrotic agents (simtuzumab), vedolizumab, and berberine, are being studied in phase 2–3 clinical trials.
PSC is a progressive bile duct disease with an overall poor prognosis; median survival after diagnosis is about 12–21 years (excluding liver transplantation). Long-term survival is possible when liver transplantation is included. The Mayo risk score (including age, bilirubin, ALP, AST, and presence of varices) is used to predict prognosis in PSC.
Cholangiocarcinoma (CCA): The most serious complication of PSC, occurring in about 7–15% of PSC patients over their lifetime. The annual incidence is about 0.5–1.5%. In some cases CCA is already present at the time of PSC diagnosis, and the incidence is particularly high within the first 1–2 years after diagnosis. When cholangiocarcinoma is suspected, serum CA 19-9, MRCP, ERCP biliary brushing cytology (biliary brushings), and FISH (fluorescence in situ hybridization) testing are performed. CCA is often already unresectable at diagnosis, so the prognosis is very poor.
Colorectal cancer (CRC) risk: In IBD with PSC (especially ulcerative colitis), the risk of colorectal cancer is known to be increased 4–5-fold compared with IBD without PSC. Colonoscopic surveillance every 1–2 years is needed from the time of PSC diagnosis.
Prognosis after liver transplantation: PSC as an indication for liver transplantation shows good post-transplant outcomes (5-year survival 85–90%). PSC recurs after transplantation in about 20–25%, appearing on average about 5–10 years later. After transplantation, IBD may worsen despite immunosuppressive treatment, and CRC risk persists after transplantation.
Owing to the autoimmune·multifactorial nature of PSC etiology, no method of primary prevention is currently known. However, secondary·tertiary prevention through early diagnosis, surveillance for complications, and active management is important.
Cholangiocarcinoma surveillance: An ideal surveillance strategy for cholangiocarcinoma in PSC has not yet been established, but most guidelines recommend annual MRCP and serum CA 19-9 measurement. When gallbladder polyps are present, the risk of gallbladder cancer is high, so periodic ultrasound and, when needed, cholecystectomy are considered.
Colorectal cancer surveillance: In PSC patients with IBD, colonoscopy every 1–2 years from the time of PSC diagnosis is recommended. Surveillance endoscopy must be maintained regardless of IBD activity, and prompt action is needed when dysplasia is found.
Osteoporosis prevention: The risk of osteoporosis is high owing to malabsorption of fat-soluble vitamin D due to cholestasis. Vitamin D and calcium supplementation, regular bone density measurement by dual-energy X-ray absorptiometry (DEXA) scan, and bisphosphonate treatment when needed are required.
Prevention of bacterial cholangitis: In patients with a dominant stricture, prophylactic oral antibiotics (e.g., ciprofloxacin) may be considered after endoscopic treatment or when there is a history of recurrent cholangitis. Prophylactic antibiotics must be given before endoscopic procedures.
Vaccination: Vaccination against hepatitis A, hepatitis B, pneumococcus, and influenza is recommended. In particular, patients awaiting liver transplantation should complete all possible vaccinations before transplantation. Live vaccines are contraindicated after transplantation.
IBD management: In IBD with PSC, IBD activity and PSC activity do not necessarily coincide, so the two diseases must be managed independently. The effect of IBD drugs such as 5-ASA on PSC progression or CRC risk is unclear, but maintaining remission of the IBD itself is important.